Enliven initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Enliven (ELVN) with a Buy rating and $36 price target Enliven’ has “highly selective and potentially best-in-class drugs” for both chronic myeloid leukaemia and HER2+ breast cancer, the analyst tells investors in a research note. The firm sees a path for accelerated approval in the second-line setting for Enliven and a different mechanism of action of ELVN-001 versus Scemblix.